Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Prospective, Randomized, Placebo Controlled, Multi-center Phase 3 Study to Evaluate Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)

NCT04484415 is registered in ClinicalTrials.gov with Asieris MediTech (Hong Kong) Co., Ltd. as lead sponsor.

NCT NCT04484415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04484415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Prospective, Randomized, Placebo Controlled, Multi-center Phase 3 Study to Evaluate Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)
Lead sponsor
Asieris MediTech (Hong Kong) Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
November 10, 2020
Completion date
December 31, 2023
Enrollment
402 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical intraepithelial neoplasia grade 2/3